Resonance Health Ltd (AU:RHT)
ASX:RHT
Want to see AU:RHT full AI Analyst Report?
RHT Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.06
Previous CloseN/A
Volume166.47K
Average Volume (3M)274.25K
Market Cap
AU$19.08M
Enterprise ValueAU$22.07M
Total Cash (Recent Filing)AU$2.69M
Total Debt (Recent Filing)AU$5.20M
Price to Earnings (P/E)26.4
Beta1.60
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding477,120,240
10 Day Avg. Volume456,299
30 Day Avg. Volume274,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.89
Price to Sales (P/S)1.60
P/FCF Ratio22.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelResonance Health's mix of software licensing/subscriptions and per-scan usage fees, plus imaging services, creates diversified, recurring revenue streams. That model supports predictable topline and aligns revenue with imaging volume trends, improving durability of cash inflows over months.
Specialized AI Imaging ExpertiseThe company's AI-enabled MRI quantification and image-analysis specialization is a high‑barrier, domain-specific capability. Clinical and research adoption cycles favor validated, niche providers, creating stickiness and competitive differentiation that supports sustainable market position.
Moderate Leverage And Capital StructureA debt-to-equity of 0.40 and a ~52.5% equity ratio indicate moderate leverage and a solid capital base. This balance sheet gives room to invest in product development or commercialisation without immediate solvency stress, supporting operational resilience across a 2–6 month horizon.
Bears Say
Negative ProfitabilityPersistent negative EBIT and net income margins show the business is not converting revenue into profits. Over months this requires continued funding or margin improvement; absent structural cost cuts or higher revenue scale, profitability weakness limits reinvestment and long-term viability.
Steep Free Cash Flow DeclineA 66.5% drop in free cash flow materially reduces internal funding for R&D, sales expansion, and working capital. Even with some operating cash generation, poor conversion to FCF raises reliance on external capital and constrains strategic options over the coming months.
Small Scale And Limited ResourcesA headcount of 18 signals a very small operating scale, which can limit sales reach, regulatory support, and product development throughput. Scaling commercial partnerships or handling large clinical trials may require rapid hires or capital, constraining growth and margin expansion durability.
Resonance Health Ltd News
RHT FAQ
What was Resonance Health Ltd’s price range in the past 12 months?
Resonance Health Ltd lowest share price was AU$0.03 and its highest was AU$0.06 in the past 12 months.
What is Resonance Health Ltd’s market cap?
Resonance Health Ltd’s market cap is AU$19.08M.
When is Resonance Health Ltd’s upcoming earnings report date?
Resonance Health Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 80 days.
How were Resonance Health Ltd’s earnings last quarter?
Resonance Health Ltd released its earnings results on Feb 26, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Resonance Health Ltd overvalued?
According to Wall Street analysts Resonance Health Ltd’s price is currently Overvalued.
Does Resonance Health Ltd pay dividends?
Resonance Health Ltd does not currently pay dividends.
What is Resonance Health Ltd’s EPS estimate?
Resonance Health Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resonance Health Ltd have?
Resonance Health Ltd has 477,120,240 shares outstanding.
What happened to Resonance Health Ltd’s price movement after its last earnings report?
Resonance Health Ltd reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Resonance Health Ltd?
Currently, no hedge funds are holding shares in AU:RHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resonance Health Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RHT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$110.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.14%
12-Months-Change
Fundamentals
Return on Equity
7.57%
Trailing 12-Months
Asset Growth
0.14%
Trailing 12-Months
Company Description
Resonance Health Ltd
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Middle East, and Africa. Its portfolio of non-invasive, MRI-based diagnostic tools includes FerriScan, a system for quantifying liver iron concentration (LIC); FerriSmart, leveraging artificial intelligence (AI) for automated, real-time assessment of LIC; HepaFat-AI, an AI-driven solution for real-time, multi-metric liver fat quantification; CardiacT2, which provides dual analysis in conjunction with FerriScan to evaluate cardiac iron accumulation; HepaFat-Scan, a non-invasive MRI method for assessing liver fat within tissue; and LiverSmart, a comprehensive non-invasive MRI device integrating FerriSmart and HepaFat-AI for a unified report. The company further extends its offerings to include quantitative imaging measurements and Contract Research Organization (CRO) services, encompassing rigorous image analysis, imaging charter development, robust project and data management, proactive issue resolution, site tracking with clinical trial progress reports, and streamlined data flow coordination. They also provide comprehensive biomarker services, covering analysis of blood, urine, and protein analytes, alongside RNA, DNA, and genotyping. Their support for multinational and multicenter clinical trials extends to protocol development, subject inclusion/exclusion criteria assessment, dose modification strategies, new therapy safety profile evaluations, and establishing primary and secondary endpoints for drug efficacy. Additionally, they supply phantoms crucial for MRI machine calibration. Its client base includes clinicians, who utilize their solutions for managing human diseases, and pharmaceutical and therapeutic companies engaged in clinical research. Established in 1987, Resonance Health Limited maintains its headquarters in Burswood, Australia.
Technical Analysis
Pro Medicus Limited
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
Artrya Limited
―
Options Prices
Currently, No data available
---